View More Recent Stories

Nov 28, 2023 08:00AM New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring for Pediatric Patients
Nov 14, 2023 04:30PM Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 1, 2023 08:00AM Nuwellis Announces Board of Directors Transition
Oct 31, 2023 08:00AM Nuwellis’ Strategic Partner, SeaStar Medical, Receives FDA Approvable Letter for Its Pediatric Selective Cytopheretic Device
Jun 20, 2023 08:32AM Nuwellis (NUWE) Enters Pilot Agreement With DaVita (DVA)
Jun 20, 2023 08:30AM Nuwellis Inc. Announces Pilot Agreement With DaVita Inc.
Jun 13, 2023 04:15PM Nuwellis to Participate in the Maxim Group Virtual Healthcare Conference
Jun 5, 2023 04:17PM Nuwellis (NUWE) Announces Appointment of Mike McCormick to its Board of Directors
Jun 5, 2023 04:15PM Nuwellis Announces the Appointment of Mike McCormick to its Board of Directors
May 22, 2023 05:10PM Nuwellis, Inc. Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Feb 23, 2023 04:15PM Nuwellis to Present at the Oppenheimer 33rd Annual Healthcare Conference
Feb 23, 2023 08:00AM Clinical Data Supports the Role of Ultrafiltration in Preventing Cardiac Surgery-Associated Acute Kidney Injury (AKI)
Dec 29, 2022 01:34PM SeaStar Medical and Nuwellis Enter into a U.S. License and Distribution Agreement for SeaStar Medical’s Selective Cytopheretic Device (SCD) for Pediatric Acute Kidney Injury (AKI)
View More Recent Stories